Preclinical study shows potential of new technologies to detect response to cancer therapy earlier

February 20, 2013
3-D Ultrasound Molecular Imaging (USMI) images of non-responder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. Credit: Dayton Lab, UNC

The research was published early in the January issue of the journal Technology in Cancer Research and Treatment. The article describes experiments using ultrasonic molecular imaging (USMI) and Dynamic Contrast Enhanced-Perfusion Imaging (DCE-PI) to measure response to therapy for pancreatic cancer.

Paul Dayton, PhD, senior author says, "What we found is that using two non-invasive technologies, we can detect response to therapy earlier than by relying on tumor volume changes. Having new non-invasive, inexpensive technologies available to measure response to therapy earlier during the course of treatment would be a significant advance in the ability to tailor a person's treatment to improve outcomes."

Dr. Dayton, an Associate Professor of Biomedical Engineering, worked with Jen Jen Yeh, MD, Associate Professor of Surgery and Pharmacology, to evaluate the imaging technologies on human in a pre-. Both faculty are members of the Lineberger Comprehensive Cancer Center.

USMI has the ability to characterize non-invasively the biologic processes at the cellular and molecular levels. It does this through the use of targeted contrast agents, which are markers that bind to specific proteins expressed on within the body. These contrast agents enable a standard to detect signals from cancer cells that would otherwise be undetectable.

Ultrasound DCE-PI is a method used to non-invasively monitor the blood flow in the microcirculation. Since growing tumors require abnormally increased blood flow, changes in blood vessel structure or density can provide information regarding tumor malignancy.

The team used a drug that inhibits a protein specific to tumors. They then used the to measure the response of two different tumors, one known to respond to the drug therapy, and a second known not to respond. The results indicated that USMI was able to detect molecular signs of tumor response to therapy after only 2 days. A change in blood flow in the tumor was observed to detect response after day 14 using DCE-PI. Over the same period, standard volume measurements were not able to detect therapeutic response, and prior studies suggested that volume measurements do not become indicative of response until approximately 28 days. Thus, these methods showed a notable improvement in the early identification of tumor to therapy, using contrast enhanced ultrasound imaging.

Although the contrast agents for USMI are not yet available in the United States, they are currently in clinical trials in Europe for cancer imaging.

Explore further: Preclinical studies use specialized ultrasound to detect presence of cancer

Related Stories

Preclinical studies use specialized ultrasound to detect presence of cancer

July 10, 2012
From the air, the twists and turns of rivers can easily be seen. In the body, however, tracing the twists and turns of blood vessels is difficult, but important. Vessel "bendiness" can indicate the presence and progression ...

Breast MRI helps predict chemotherapy's effectiveness

May 23, 2012
Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online ...

MRI may be noninvasive method to measure breast cancer prognosis

December 8, 2011
Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients ...

DAI provides potential imaging biomarker to indicate brain tumor response to RT

February 8, 2013
Diffusion abnormality index (DAI) shows promise as an imaging biomarker to measure brain tumor response to radiation therapy, according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. ...

Noninvasive measurement enables use of IFP as potential biomarker for tumor aggressiveness

October 1, 2012
Researchers validated a method of noninvasive imaging that provides valuable information about interstitial fluid pressure of solid tumors and may aid in the identification of aggressive tumors, according to the results of ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.